Semaglutide Withdrawal: Gradual Reduction vs. Abrupt Cessation for Weight Maintenance
Background
Semaglutide, a GLP-1 receptor agonist (a class of drugs that mimic a natural hormone to regulate blood sugar and appetite), is highly effective for weight loss in individuals with obesity. However, significant weight regain is common after treatment discontinuation, often due to adaptations in appetite control and energy balance. There is a critical lack of clinical data on optimal strategies for discontinuing semaglutide to sustain weight loss and manage cardiometabolic health.
Study Design
This Phase 3 randomized controlled trial, sponsored by Mount Sinai Hospital, will enroll an estimated 98 participants with obesity who have achieved weight reduction on semaglutide. The study, commencing in February 2026 and completing in May 2029, will compare two withdrawal strategies over 16 weeks. One group will undergo gradual dose reduction of semaglutide, decreasing their dosage by 25% every 4 weeks until complete cessation. The active comparator group will experience abrupt cessation of semaglutide at week 16.
Results
As a recruiting Phase 3 clinical trial (NCT07294950), specific findings are not yet available. However, the study aims to determine if a gradual semaglutide withdrawal strategy can mitigate the common weight regain observed after abrupt cessation. Researchers will investigate the impact on cardiometabolic profiles, blood pressure, and appetite regulation in both groups. The trial hypothesizes that a slower reduction will lead to more sustained weight management and better physiological adaptation, potentially reducing the homeostatic response (the body's natural tendency to return to a set point) related to hedonic eating (eating for pleasure rather than hunger). The primary objective is to identify a superior strategy for long-term weight maintenance and improved cardiometabolic outcomes following semaglutide treatment discontinuation.
Key Findings
- Investigating if gradual semaglutide reduction leads to less weight regain compared to abrupt cessation in 98 participants with obesity.
- Assessing the impact of different withdrawal strategies on blood pressure monitoring and overall cardiometabolic profile changes over 16 weeks.
- Examining how gradual vs. abrupt cessation methods affect appetite regulation and the physiology of energy balance post-treatment.
- Comparing the long-term weight maintenance capabilities of gradual versus abrupt semaglutide discontinuation strategies.
Why It Matters
This study addresses a crucial gap in managing obesity post-GLP-1 agonist therapy, which has significant implications for patient care and public health. If gradual withdrawal proves superior, it could establish a new standard of care, potentially leading to improved sustained weight loss and better cardiometabolic health outcomes for millions of individuals. The findings from this Phase 3 trial are essential and will directly inform clinical guidelines for semaglutide discontinuation, influencing future treatment protocols and potentially leading to widespread adoption in clinical practice.
semaglutide
obesity
weight loss
withdrawal
cardiometabolic
phase 3